Evidence map›Paper›PMID 33523951›Full record

ArticleScience advances2021

A microneedle platform for buccal macromolecule delivery.

Ester Caffarel-Salvador, Soyoung Kim, Vance Soares, Ryan Yu Tian, Sarah R Stern, Daniel Minahan, Raissa Yona, Xiaoya Lu, Fauziah R Zakaria, Joy Collins and 18 more

Abstract read
In one paragraph

Article in Science advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. [Oral mucosal administration].Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology · 2026
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Progressive microneedles for targeting and intelligent drug delivery.Asian journal of pharmaceutical sciences · 2025
    Review
  18. Microneedles at the Forefront of Next Generation Theranostics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Ester Caffarel-SalvadorInstitute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0002-2844-7598
Soyoung KimDepartment of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0002-4076-6807
Vance SoaresDepartment of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0002-4094-3316
Ryan Yu TianDepartment of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Sarah R SternDepartment of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0002-6518-7289
Daniel MinahanDepartment of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0003-3065-055X
Raissa YonaDepartment of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0002-1283-2811
Xiaoya LuDepartment of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Fauziah R ZakariaDepartment of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0002-6517-9289
Joy CollinsDepartment of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0002-9232-4517
Jacob WainerDepartment of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Jessica WongDepartment of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Rebecca McManusDepartment of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0003-3474-7391
Siddartha TamangDepartment of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Shane McDonnellDepartment of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Keiko IshidaDepartment of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0003-0894-296X
Alison HaywardDepartment of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0002-9581-8563
Xiewen LiuDepartment of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
František HubálekGlobal Research Technologies, Global Drug Discovery, and Device R&D, Novo Nordisk A/S, Måløv, Denmark.ORCID 0000-0003-3983-7900
Johannes FelsGlobal Research Technologies, Global Drug Discovery, and Device R&D, Novo Nordisk A/S, Måløv, Denmark.ORCID 0000-0002-6616-6746
Andreas VeggeGlobal Research Technologies, Global Drug Discovery, and Device R&D, Novo Nordisk A/S, Måløv, Denmark.
Morten Revsgaard FrederiksenGlobal Research Technologies, Global Drug Discovery, and Device R&D, Novo Nordisk A/S, Måløv, Denmark.ORCID 0000-0003-0000-4426
Ulrik RahbekGlobal Research Technologies, Global Drug Discovery, and Device R&D, Novo Nordisk A/S, Måløv, Denmark.ORCID 0000-0002-1255-0232
Tadayuki YoshitakeDepartment of Electrical Engineering and Computer Science and Research Laboratory of Electronics, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
James FujimotoDepartment of Electrical Engineering and Computer Science and Research Laboratory of Electronics, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0002-0828-4357
Niclas RoxhedDepartment of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0002-7147-6730
Robert LangerInstitute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. rlanger@mit.edu cgt20@mit.edu.ORCID 0000-0003-4255-0492
Giovanni TraversoDepartment of Chemical Engineering and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. rlanger@mit.edu cgt20@mit.edu.ORCID 0000-0001-7851-4077

Funding

CONTROLLED RELEASE OF MACROMOLECULESR01EB000244 · NIBIB · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI LANGER, ROBERT SAMUEL, TRAVERSO, CARLO GIOVANNI · 2002 to 2021
$6.1M
Controlled Release of MacromoleculesR37EB000244 · NIBIB · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI LANGER, ROBERT SAMUEL · 2008 to 2017
$3.9M
NIBIB NIH HHS R01 EB000244NIBIB NIH HHS R37 EB000244
6 · The paper itself

Abstract

Alternative means for drug delivery are needed to facilitate drug adherence and administration. Microneedles (MNs) have been previously investigated transdermally for drug delivery. To date, drug loading into MNs has been limited by drug solubility in the polymeric blend. We designed a highly drug-loaded MN patch to deliver macromolecules and applied it to the buccal area, which allows for faster delivery than the skin. We successfully delivered 1-mg payloads of human insulin and human growth hormone to the buccal cavity of swine within 30 s. In addition, we conducted a trial in 100 healthy volunteers to assess potential discomfort associated with MNs when applied in the oral cavity, identifying the hard palate as the preferred application site. We envisage that MN patches applied on buccal surfaces could increase medication adherence and facilitate the painless delivery of biologics and other drugs to many, especially for the pediatric and elderly populations.

Identifiers

PMID33523951
PMCPMC10964974

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.